GlassScriptPhysician profile
Kathryn Thomas
NPI 1699915744
$2,471.46
in general payments reported to CMS, 2019-2025
25 companies · $830 in 2025
The $830 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.33 · 2022: $321 · 2023: $85.57 · 2024: $1,206 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $245.71 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $217.35 | 2022-2025 | |
| Exact Sciences Corporation | $214.03 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $204.77 | 2021-2025 | |
| Novo Nordisk INC | $204.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $173.19 | 2022-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $139.46 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Lilly USA, LLC | $139.26 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $93.32 | 2023-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $88.82 | 2024-2025 | Spravato |
| Glaxosmithkline, LLC. | $79.14 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Daiichi Sankyo INC. | $78.99 | 2024 | Injectafer |
| Boston Scientific Corporation | $71.77 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Axsome Therapeutics, INC. | $67.77 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.26 | 2022-2025 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $59.90 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $56.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.31 | 2022 | |
| Corcept Therapeutics | $44.90 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $42.53 | 2022-2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $40.39 | 2024-2025 | Camzyos, Eliquis |
| Mylan Specialty L.P. | $34.89 | 2024 | Yupelri |
| Amneal Pharmaceuticals LLC | $23.27 | 2025 | Unithroid |
| Cranial Technologies, INC | $17.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.